Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Haematologica ; 108(2): 457-471, 2023 02 01.
Article in English | MEDLINE | ID: mdl-35950535

ABSTRACT

Chimeric antigen receptor (CAR) T-cell immunotherapies targeting CD19 or CD22 induce remissions in the majority of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), although relapse due to target antigen loss or downregulation has emerged as a major clinical dilemma. Accordingly, great interest exists in developing CAR T cells directed against alternative leukemia cell surface antigens that may help to overcome immunotherapeutic resistance. The fms-like tyrosine kinase 3 receptor (FLT3) is constitutively activated via FLT3 mutation in acute myeloid leukemia (AML) or wild-type FLT3 overexpression in KMT2A (lysine-specific methyltransferase 2A)-rearranged ALL, which are associated with poor clinical outcomes in children and adults. We developed monovalent FLT3-targeted CAR T cells (FLT3CART) and bispecific CD19xFLT3CART and assessed their anti-leukemia activity in preclinical models of FLT3-mutant AML and KMT2A-rearranged infant ALL. We report robust in vitro FLT3CART-induced cytokine production and cytotoxicity against AML and ALL cell lines with minimal cross-reactivity against normal hematopoietic and non-hematopoietic tissues. We also observed potent in vivo inhibition of leukemia proliferation in xenograft models of both FLT3-mutant AML and KMT2A-rearranged ALL, including a post-tisagenlecleucel ALL-to-AML lineage switch patient-derived xenograft model pairing. We further demonstrate significant in vitro and in vivo activity of bispecific CD19xFLT3CART against KMT2Arearranged ALL and posit that this additional approach might also diminish potential antigen escape in these high-risk leukemias. Our preclinical data credential FLT3CART as a highly effective immunotherapeutic strategy for both FLT3- mutant AML and KMT2A-rearranged ALL which is poised for further investigation and clinical translation.


Subject(s)
Leukemia, Myeloid, Acute , Precursor Cell Lymphoblastic Leukemia-Lymphoma , Receptors, Chimeric Antigen , Adult , Child , Humans , Receptors, Chimeric Antigen/genetics , Leukemia, Myeloid, Acute/genetics , Immunotherapy , T-Lymphocytes/metabolism , fms-Like Tyrosine Kinase 3/genetics
2.
Nat Commun ; 8: 15494, 2017 05 30.
Article in English | MEDLINE | ID: mdl-28555642

ABSTRACT

Pulmonary arterial hypertension (PAH) is an obstructive disease of the precapillary pulmonary arteries. Schistosomiasis-associated PAH shares altered vascular TGF-ß signalling with idiopathic, heritable and autoimmune-associated etiologies; moreover, TGF-ß blockade can prevent experimental pulmonary hypertension (PH) in pre-clinical models. TGF-ß is regulated at the level of activation, but how TGF-ß is activated in this disease is unknown. Here we show TGF-ß activation by thrombospondin-1 (TSP-1) is both required and sufficient for the development of PH in Schistosoma-exposed mice. Following Schistosoma exposure, TSP-1 levels in the lung increase, via recruitment of circulating monocytes, while TSP-1 inhibition or knockout bone marrow prevents TGF-ß activation and protects against PH development. TSP-1 blockade also prevents the PH in a second model, chronic hypoxia. Lastly, the plasma concentration of TSP-1 is significantly increased in subjects with scleroderma following PAH development. Targeting TSP-1-dependent activation of TGF-ß could thus be a therapeutic approach in TGF-ß-dependent vascular diseases.


Subject(s)
Bone Marrow Cells/metabolism , Hypertension, Pulmonary/etiology , Hypertension, Pulmonary/parasitology , Hypoxia/complications , Schistosoma/physiology , Thrombospondin 1/metabolism , Transforming Growth Factor beta/metabolism , Animals , Antigens, Ly/metabolism , Basic Helix-Loop-Helix Transcription Factors/metabolism , Cattle , Humans , Hypertension, Pulmonary/genetics , Hypertension, Pulmonary/immunology , Hypoxia/pathology , Lung/blood supply , Lung/metabolism , Lung/pathology , Mice, Inbred C57BL , Monocytes/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Signal Transduction , Th2 Cells/immunology , Thrombospondin 1/blood , Thrombospondin 1/genetics
3.
High Alt Med Biol ; 18(1): 61-66, 2017 Mar.
Article in English | MEDLINE | ID: mdl-28061144

ABSTRACT

Robinson, Jeffrey C., Cheryl Abbott, Christina A. Meadows, Robert C. Roach, Benjamin Honigman, and Todd M. Bull. Long-term health outcomes in high-altitude pulmonary hypertension. High Alt Med Biol. 18:61-66, 2017. BACKGROUND: High-altitude pulmonary hypertension (HAPH) is one of several known comorbidities that effect populations living at high altitude, but there have been no studies looking at long-term health consequences of HAPH. We aimed to determine whether HAPH during adolescence predisposes to significant pulmonary hypertension (PH) later in life, as well as identify how altitude exposure and HAPH correlate with functional class and medical comorbidities. METHODS: We utilized a previously published cohort of 28 adolescents from Leadville, Colorado, that underwent right heart catheterization at 10,150 ft (3094 m) in 1962, with many demonstrating PH as defined by resting mean pulmonary arterial pressure ≥25 mmHg. We located participants of the original study and had living subjects complete demographic and health surveys to assess for the presence of PH and other medical comorbidities, along with current functional status. RESULTS: Seventy-five percent of the individuals who participated in the original study were located. Those with HAPH in the past were more prone to have exertional limitation corresponding to WHO functional class >1. Fifty-five years following the original study, we found no significant differences in prevalence of medical comorbidities, including PH, among those with and without HAPH in their youth. CONCLUSIONS: Surveyed individuals did not report significant PH, but those with HAPH in their youth were more likely to report functional limitation. With a significant worldwide population living at moderate and high altitudes, further study of long-term health consequences is warranted.


Subject(s)
Altitude Sickness/physiopathology , Altitude , Hypertension, Pulmonary/physiopathology , Patient Outcome Assessment , Time Factors , Adolescent , Aged , Cohort Studies , Colorado , Female , Follow-Up Studies , Health Surveys , Humans , Male , Middle Aged
4.
Crit Care ; 17(3): R92, 2013 May 24.
Article in English | MEDLINE | ID: mdl-23706007

ABSTRACT

INTRODUCTION: We sought to determine whether higher levels of the novel biomarker growth differentiation factor-15 (GDF-15) are associated with poor outcomes and the presence of pulmonary vascular dysfunction (PVD) in patients with acute respiratory distress syndrome (ARDS). METHODS: We conducted a retrospective cohort study in patients enrolled in the Acute Respiratory Distress Syndrome Network Fluid and Catheter Treatment (FACT) Trial. Patients enrolled in the FACT Trial who received a pulmonary artery catheter (PAC), had plasma available from the same study day and sufficient hemodynamic data to determine the presence of PVD were included. Logistic regression was used to determine the association between GDF-15 level and 60-day mortality. RESULTS: Of the 513 patients enrolled in the FACT Trial assigned to receive a PAC, 400 were included in this analysis. Mortality at 60 days was significantly higher in patients whose GDF-15 levels were in the third (28%) or fourth (49%) quartile when compared to patients with GDF-15 levels in the first quartile (12%) (P <0.001). Adjusting for severity of illness measured by APACHE III score, the odds of death for patients with GDF-15 levels in the fourth quartile when compared to the first quartile was 4.26 (95% CI 2.18, 10.92, P <0.001). When added to APACHE III alone for prediction of 60-day mortality, GDF-15 levels increased the area under the receiver operating characteristic curve from 0.72 to 0.77. At an optimal cutoff of 8,103 pg/mL, the sensitivity and specificity of GDF-15 for predicting 60-day mortality were 62% (95% CI 53%, 71%) and 76% (95% CI 71%, 81%), respectively. Levels of GDF-15 were not useful in identifying the presence of PVD, as defined by hemodynamic measurements obtained by a PAC. CONCLUSIONS: In patients with ARDS, higher levels of GDF-15 are significantly associated with poor outcome but not PVD.


Subject(s)
Growth Differentiation Factor 15/blood , Respiratory Distress Syndrome/blood , Adult , Biomarkers/blood , Catheterization, Swan-Ganz , Female , Fluid Therapy , Humans , Male , Middle Aged , Prognosis , Pulmonary Artery/physiopathology , Respiratory Distress Syndrome/mortality , Respiratory Distress Syndrome/physiopathology , Respiratory Distress Syndrome/therapy , Retrospective Studies
5.
Chest ; 139(5): 994-1002, 2011 May.
Article in English | MEDLINE | ID: mdl-20829333

ABSTRACT

BACKGROUND: Growth differentiation factor (GDF)-15 is a secreted member of the transforming growth factor-ß cytokine superfamily. GDF-15 levels are elevated in the serum of patients with cardiovascular diseases. We hypothesized that GDF-15 levels would also be increased in the plasma and lung tissue of patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH). METHODS: GDF-15 levels were measured in plasma in subjects with SSc-PAH (n = 30) and compared with subjects with systemic sclerosis (SSc) without pulmonary arterial hypertension (PAH) (n = 24). Patients with idiopathic PAH (IPAH) (n = 44) and normal individuals (n = 13) served as control subjects. Immunohistochemistry and immunofluorescence assay identified GDF-15 protein in lung tissue from patients with SSc-PAH and IPAH. RESULTS: Patients with SSc-PAH had significantly higher mean circulating levels of GDF-15 in plasma compared with patients with SSc without PAH (422.3 ± 369.5 pg/mL vs 108.1 ± 192.8 pg/mL, P = .004). GDF-15 levels correlated positively with estimated right ventricular systolic pressure on echocardiogram and plasma levels of the amino terminal propeptide form of brain natriuretic peptide. There was an inverse correlation between circulating GDF-15 and diffusing capacity of the lung for carbon monoxide (Dlco) and a positive correlation with the FVC to Dlco ratio on pulmonary function test. GDF-15 levels > 125 pg/mL were associated with reduced survival. GDF-15 protein expression was increased in lung tissue from patients with SSc-PAH. CONCLUSIONS: GDF-15 may be a useful biomarker in PAH associated with SSc. Its presence in lung tissue may suggest a role in the pathology of the disease.


Subject(s)
Growth Differentiation Factor 15/biosynthesis , Hypertension, Pulmonary/etiology , Hypertension, Pulmonary/metabolism , Scleroderma, Systemic/complications , Scleroderma, Systemic/metabolism , Female , Growth Differentiation Factor 15/analysis , Humans , Male , Middle Aged
6.
Clin Transl Sci ; 3(5): 210-8, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20973920

ABSTRACT

Pulmonary arterial hypertension is a common and fatal complication of scleroderma that may involve inflammatory and autoimmune mechanisms. Alterations in the gene expression of peripheral blood mononuclear cells have been previously described in patients with pulmonary arterial hypertension. Our goal is to identify differentially expressed genes in peripheral blood mononuclear cells in scleroderma patients with and without pulmonary hypertension as biomarkers of disease. Gene expression analysis was performed on a Microarray Cohort of scleroderma patients with (n = 10) and without (n = 10) pulmonary hypertension. Differentially expressed genes were confirmed in the Microarray Cohort and validated in a Validation Cohort of scleroderma patients with (n = 15) and without (n = 19) pulmonary hypertension by RT-qPCR. We identified inflammatory and immune-related genes including interleukin-7 receptor (IL-7R) and chemokine receptor 7 as differentially expressed in patients with scleroderma-associated pulmonary hypertension. Flow cytometry confirmed decreased expression of IL-7R on circulating CD4+ T-cells from scleroderma patients with pulmonary hypertension. Differences exist in the expression of inflammatory and immune-related genes in peripheral blood cells from patients with scleroderma-related pulmonary hypertension compared to those with normal pulmonary artery pressures. These findings may have implications as biomarkers to screen at-risk populations for early diagnosis and provide insight into mechanisms of scleroderma-related pulmonary hypertension.


Subject(s)
Blood Cells/immunology , Scleroderma, Systemic/blood , Scleroderma, Systemic/complications , CD4-Positive T-Lymphocytes/immunology , Cluster Analysis , Cohort Studies , Demography , Familial Primary Pulmonary Hypertension , Female , Flow Cytometry , Hemodynamics , Humans , Hypertension, Pulmonary/blood , Hypertension, Pulmonary/etiology , Hypertension, Pulmonary/genetics , Hypertension, Pulmonary/immunology , Male , Middle Aged , Oligonucleotide Array Sequence Analysis , Phenotype , Receptors, Interleukin-7/immunology , Reproducibility of Results , Reverse Transcriptase Polymerase Chain Reaction , Scleroderma, Systemic/genetics , Scleroderma, Systemic/immunology
7.
Am J Respir Cell Mol Biol ; 39(6): 706-16, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18587055

ABSTRACT

Human herpesvirus-8 (HHV-8) is the causative agent of Kaposi's sarcoma and is associated with the angioproliferative disorders primary effusion lymphoma and multicentric Castleman's disease. Evidence of HHV-8 infection within the pulmonary vasculature of patients with idiopathic pulmonary arterial hypertension (IPAH) has been described. We hypothesize that HHV-8 infection of pulmonary microvascular endothelial cells results in an apoptotic-resistant phenotype characteristic of severe pulmonary arterial hypertension. Our objective was to investigate the ability of HHV-8 to infect human pulmonary microvascular endothelial cells in vitro and characterize the phenotypic effect of this infection. Human pulmonary microvascular endothelial cells were exposed to HHV-8 using two methods (direct virus and co-culture technique). The presence of lytic and latent infection was confirmed. Changes in endothelial cell gene and protein expression and effects on cellular apoptosis were measured. HHV-8 can both lytically and latently infect primary human pulmonary microvascular endothelial cells in vitro. HHV-8 infection results in significant changes in gene expression, including alterations of pathways important to cellular apoptosis. HHV-8 infection also alters expression of genes integral to the bone morphogenic protein pathway, including down-regulation of bone morphogenic protein-4. Other genes previously implicated in the development of PAH are affected by HHV-8 infection, and cells infected with HHV-8 are resistant to apoptosis.


Subject(s)
Blood Vessels/cytology , Blood Vessels/virology , Endothelial Cells/virology , Herpesviridae Infections/metabolism , Apoptosis/drug effects , Blood Vessels/enzymology , Bone Morphogenetic Protein 4/pharmacology , Carrier Proteins/pharmacology , Caspase 3/metabolism , Caspase 7/metabolism , Cells, Cultured , Culture Media, Conditioned , Endothelial Cells/cytology , Endothelial Cells/drug effects , Endothelial Cells/enzymology , Enzyme-Linked Immunosorbent Assay , Fluorescent Antibody Technique , Gene Expression Regulation/drug effects , Herpesvirus 8, Human , In Situ Nick-End Labeling , Interleukin-6/pharmacology , Oligonucleotide Array Sequence Analysis , Phenotype , Polymerase Chain Reaction , Reproducibility of Results
8.
Rev. biol. trop ; 51(supl. 4): 77-81, jun. 2003. tab
Article in English | LILACS | ID: lil-388933

ABSTRACT

We observed the behavior and ecology of Chaetodon capistratus infected and uninfected with the ectoparasitic isopod Anilocra chaetodontis to assess whether there may be parasite induced alterations in host biology, host defenses against infection, and/or pathology related to infection. We also examined habitat related differences in infection rates. Infected fish had higher rates of interaction with conspecifics and spent more time in low flow environments (which might improve transmission of juvenile parasites to new hosts). Butterfly fish without isopods were chased more frequently by damselfishes, fed more, and had larger territories. Time spent near conspecifics, and fish condition and gonadosomatic index did not vary between infected and uninfected fish. These results suggest that foureye butterfly fish behavior is altered by the isopod parasite in order for the isopods to more easily gain mates or transmit offspring to new hosts.


Subject(s)
Animals , Male , Female , Behavior, Animal , Ectoparasitic Infestations , Fish Diseases , Perciformes , Ecosystem , Host-Parasite Interactions
9.
Rev Biol Trop ; 51 Suppl 4: 77-81, 2003 Jun.
Article in English | MEDLINE | ID: mdl-15264556

ABSTRACT

We observed the behavior and ecology of Chaetodon capistratus infected and uninfected with the ectoparasitic isopod Anilocra chaetodontis to assess whether there may be parasite induced alterations in host biology, host defenses against infection, and/or pathology related to infection. We also examined habitat related differences in infection rates. Infected fish had higher rates of interaction with conspecifics and spent more time in low flow environments (which might improve transmission of juvenile parasites to new hosts). Butterfly fish without isopods were chased more frequently by damselfishes, fed more, and had larger territories. Time spent near conspecifics, and fish condition and gonadosomatic index did not vary between infected and uninfected fish. These results suggest that foureye butterfly fish behavior is altered by the isopod parasite in order for the isopods to more easily gain mates or transmit offspring to new hosts.


Subject(s)
Behavior, Animal , Ectoparasitic Infestations/veterinary , Fish Diseases/parasitology , Isopoda/physiology , Perciformes/parasitology , Animals , Ecosystem , Female , Host-Parasite Interactions/physiology , Male
10.
Pharmacotherapy ; 22(12): 1517-23, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12495161

ABSTRACT

STUDY OBJECTIVE: To evaluate the antimicrobial properties of tigecycline, both alone and in combination with other antibiotics, against multidrug-resistant strains of Enterococcus faecium and Staphylococcus aureus. DESIGN: In vitro study. SETTING: University laboratory. MEASUREMENTS AND MAIN RESULTS: Tigecycline, both alone and in combination with other antimicrobial agents, was evaluated against two strains of vancomycin-resistant E. faecium (VREF), three glycopeptide-intermediately resistant S. aureus strains, and one methicillin-resistant S. aureus strain. Tigecycline's activity was compared with that of vancomycin, gentamicin, rifampin, and doxycycline, using time-kill studies and analysis of minimum inhibitory concentrations and minimum bactericidal concentrations. Tigecycline also was evaluated in combination with vancomycin, gentamicin, rifampin, and doxycycline in time-kill studies. The number of log10 colony-forming units/ml at 24 hours was compared among treatment groups and growth control by analysis of variance. All isolates were susceptible to tigecycline, regardless of their susceptibilities to vancomycin or doxycycline. In time-kill studies, tigecycline significantly inhibited the bacterial inoculum of all isolates (p < 0.05). Although none of the tigecycline combinations studied had enhanced killing activity against VREF, when gentamicin was combined with tigecycline, improved effects were found against both strains. Against three of the S. aureus strains tested, the combination of gentamicin and tigecycline demonstrated enhanced or improved activity independently of each strain's susceptibility to gentamicin. CONCLUSION: The multidrug-resistant, gram-positive bacteria tested, including doxycycline-resistant isolates, were susceptible to tigecycline. The combination of tigecycline and gentamicin may have improved or enhanced activity against strains of vancomycin-resistant enterococci and S. aureus.


Subject(s)
Drug Therapy, Combination/pharmacology , Enterococcus faecium/drug effects , Minocycline/analogs & derivatives , Minocycline/pharmacology , Staphylococcus aureus/drug effects , Anti-Bacterial Agents/pharmacology , Drug Resistance, Bacterial/physiology , Microbial Sensitivity Tests/statistics & numerical data , Tigecycline
SELECTION OF CITATIONS
SEARCH DETAIL
...